OPKO Completes Pivotal Phase 3 Study for Somatrogon (hGH-CTP), an Investigational Long-Acting Growth Hormone Being Studied for the Treatment of Children With Growth Hormone Deficiency

World News: . []

MIAMI Aug 29 2019 GLOBE NEWSWIRE -- today announced that the last LINK  has completed the final visit in the Companys LINK  Phase 3 study evaluating the safety and efficacy of the once LINK  somatrogon hGH-CTP for treatment of grow th horm...

More news and information about OPKO Health, Inc.

Published By:

Globe Newswire: 14:24 GMT Thursday 29th August 2019

Published: .

Search for other references to "opko" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
Privacy Policy | Terms and Conditions | Contact Us